Brendon L. Neuen

Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

Aminu K. Bello, Adeera Levin, Meaghan Lunney et al. · BMJ · 2019 · 257 citations · Full text

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart et al. · Circulation · 2023 · 252 citations · Full text

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal et al. · Circulation · 2018 · 245 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9